pharmaphorum5m
New UK biotech Swarm lands with T-cell therapy mission
Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
BIA report: UK biotech investment surged to £3.5bn in 2024
The UK biotech sector raised £3.5bn in 2024, marking a 94% increase from the previous year, according to the BioIndustry ...
Maze Therapeutics targets up to $728 million valuation in US IPO
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
Morgan Stanley cuts Intellia stock rating amid gene editing concerns
Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...
FierceBiotech6h
Though prevalent in the lab and middle management, east Asian Americans are underrepresented in biopharma C-suites: report
Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. | Despite making up a sizable ...
NL Times6h
Amsterdam UMC takes Ronald Plasterk to court for patent fraud
The Amsterdam UMC has sued Ronald Plasterk and the biotech firm CureVac for failing to credit the hospital and its scientist, ...